Cargando…

CMTM6 expression in M2 macrophages is a potential predictor of PD-1/PD-L1 inhibitor response in colorectal cancer

BACKGROUND: CMTM6 is a novel key regulator of PD-L1. High expression of both CMTM6 and PD-L1 may predict the benefit of PD-1 axis blockade in lung cancer. We aimed to investigate the expression pattern of CMTM6 between mismatch repair-defective (dMMR) and mismatch repair-proficient (pMMR) colorectal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Xuehui, Lan, Xiaoliang, Hu, Wanming, Zhang, Wanning, Lai, Xiangmeng, Xu, Shaowan, Li, Jiaoying, Qiu, Weihao, Wang, Wei, Xiao, Jianbiao, Wang, Feifei, Ding, Yanqing, Liang, Li
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8505364/ https://www.ncbi.nlm.nih.gov/pubmed/33818637 http://dx.doi.org/10.1007/s00262-021-02931-6

Ejemplares similares

Identification of CMTM6 and CMTM4 as PD-L1 protein regulators
por: Mezzadra, Riccardo, et al.
Publicado: (2017)

CMTM6 and CMTM4 as two novel regulators of PD-L1 modulate the tumor microenvironment
por: Zhang, Tong, et al.
Publicado: (2022)

CMTM6, the newly identified PD-L1 regulator, correlates with PD-L1 expression in lung cancers
por: Gao, Feng, et al.
Publicado: (2019)

Coexpression of CMTM6 and PD-L1 as a predictor of poor prognosis in macrotrabecular-massive hepatocellular carcinoma
por: Liu, Li-Li, et al.
Publicado: (2020)

Expression Analysis of Canine CMTM6 and CMTM4 as Potential Regulators of the PD-L1 Protein in Canine Cancers
por: Takeuchi, Hiroto, et al.
Publicado: (2020)

CMTM6 and CMTM7: New leads for PD‐L1 regulation in breast cancer cells undergoing EMT
por: Xiao, Malina, et al.
Publicado: (2022)

Analysis of CMTM6 and CMTM4 expression as potential regulators of the PD-L1 protein and its association with prognosis in glioma cancer
por: Xue, Hui, et al.
Publicado: (2022)

Epithelial to Mesenchymal Transition Regulates Surface PD-L1 via CMTM6 and CMTM7 Induction in Breast Cancer
por: Xiao, Malina, et al.
Publicado: (2021)

CMTM6 significantly relates to PD-L1 and predicts the prognosis of gastric cancer patients
por: Li, Xin, et al.
Publicado: (2020)

Co-expression of CMTM6 and PD-L1: a novel prognostic indicator of gastric cancer
por: Zhang, Chao, et al.
Publicado: (2021)

Expression and Clinical Significance of CMTM6 and PD-L1 in Triple-Negative Breast Cancer
por: Shi, Shuai, et al.
Publicado: (2022)

Co-Expression with Membrane CMTM6/4 on Tumor Epithelium Enhances the Prediction Value of PD-L1 on Anti-PD-1/L1 Therapeutic Efficacy in Gastric Adenocarcinoma
por: Wang, Ziqi, et al.
Publicado: (2021)

The association of CMTM6 expression with prognosis and PD-L1 expression in triple-negative breast cancer
por: Tian, Yiping, et al.
Publicado: (2021)

HAO1-mediated oxalate metabolism promotes lung pre-metastatic niche formation by inducing neutrophil extracellular traps
por: Zeng, Zhicheng, et al.
Publicado: (2022)

HuR up-regulates cell surface PD-L1 via stabilizing CMTM6 transcript in cancer
por: Liu, Yanbin, et al.
Publicado: (2021)

CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer
por: Peng, Qi-Hua, et al.
Publicado: (2021)

Suppression of Tumor or Host Intrinsic CMTM6 Drives Antitumor Cytotoxicity in a PD-L1–Independent Manner
por: Long, Yiru, et al.
Publicado: (2023)

CMTM6-Deficient Monocytes in ANCA-Associated Vasculitis Fail to Present the Immune Checkpoint PD-L1
por: Zeisbrich, Markus, et al.
Publicado: (2021)

CMTM6 Stabilizes PD‐L1 Expression and Is a New Prognostic Impact Factor in Hepatocellular Carcinoma
por: Yugawa, Kyohei, et al.
Publicado: (2020)

Inhibition of CMTM4 Sensitizes Cholangiocarcinoma and Hepatocellular Carcinoma to T Cell–Mediated Antitumor Immunity Through PD‐L1
por: Chui, Noreen Nog‐Qin, et al.
Publicado: (2021)

PD-1/PD-L1 blockades in non-small-cell lung cancer therapy
por: Jing, Wang, et al.
Publicado: (2016)

Circular RNA hsa_circ_0067842 facilitates tumor metastasis and immune escape in breast cancer through HuR/CMTM6/PD-L1 axis
por: Li, Juan, et al.
Publicado: (2023)

Tumor-Associated Macrophages Regulate PD-1/PD-L1 Immunosuppression
por: Pu, Yunzhou, et al.
Publicado: (2022)

Defects in Macrophage Reprogramming in Cancer Therapy: The Negative Impact of PD-L1/PD-1
por: Cai, Hao, et al.
Publicado: (2021)

Radiation recall pneumonitis induced by PD-1/PD-L1 blockades: mechanisms and therapeutic implications
por: Teng, Feifei, et al.
Publicado: (2020)

PD-1-expressing macrophages and CD8 T cells are independent predictors of clinical benefit from PD-1 inhibition in advanced mesothelioma
por: Homicsko, Krisztian, et al.
Publicado: (2023)

Beyond T Cells: Understanding the Role of PD-1/PD-L1 in Tumor-Associated Macrophages
por: Lu, Di, et al.
Publicado: (2019)

The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy
por: Qian, Jiawen, et al.
Publicado: (2018)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

Inhibition of CCL7 derived from Mo-MDSCs prevents metastatic progression from latency in colorectal cancer
por: Ren, Xiaoli, et al.
Publicado: (2021)

Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers
por: Zhang, Hao, et al.
Publicado: (2023)

TGF-β: A novel predictor and target for anti-PD-1/PD-L1 therapy
por: Yi, Ming, et al.
Publicado: (2022)

PD-L1 methylation restricts PD-L1/PD-1 interactions to control cancer immune surveillance
por: Huang, Changsheng, et al.
Publicado: (2023)

Identification of PD-1 ligands: PD-L1 and PD-L2 on macrophages in lung cancer milieu by flow cytometry
por: Kwiecień, Iwona, et al.
Publicado: (2021)

Different Induction of PD-L1 (CD274) and PD-1 (CD279) Expression in THP-1-Differentiated Types 1 and 2 Macrophages
por: Lai, Chun-Yi, et al.
Publicado: (2021)

Expression and clinical significance of CMTM1 in hepatocellular carcinoma
por: Song, Xin, et al.
Publicado: (2021)

The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients
por: Sui, Xinbing, et al.
Publicado: (2015)

Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy
por: Zhao, Pengfei, et al.
Publicado: (2019)

circ-0000512 inhibits PD-L1 ubiquitination through sponging miR-622/CMTM6 axis to promote triple-negative breast cancer and immune escape
por: Dong, Li-Feng, et al.
Publicado: (2023)

Regulatory Effect of PD1/PD-Ligand 1 (PD-L1) on Treg Cells in Patients with Idiopathic Pulmonary Fibrosis
por: Wang, Bing, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_53j87sv4u1nkma25l5etokg429